000304272 001__ 304272
000304272 005__ 20250907022502.0
000304272 0247_ $$2doi$$a10.1038/s41408-025-01351-4
000304272 0247_ $$2pmid$$apmid:40883272
000304272 0247_ $$2pmc$$apmc:PMC12397487
000304272 0247_ $$2altmetric$$aaltmetric:180996171
000304272 037__ $$aDKFZ-2025-01813
000304272 041__ $$aEnglish
000304272 082__ $$a610
000304272 1001_ $$0P:(DE-He78)be2bee623c6815bb57b390a0ecb8072a$$aGüler, Murat$$b0$$eFirst author$$udkfz
000304272 245__ $$aClustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study.
000304272 260__ $$a[London]$$bSpringer Nature$$c2025
000304272 3367_ $$2DRIVER$$aarticle
000304272 3367_ $$2DataCite$$aOutput Types/Journal article
000304272 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756716473_32343
000304272 3367_ $$2BibTeX$$aARTICLE
000304272 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304272 3367_ $$00$$2EndNote$$aJournal Article
000304272 500__ $$a#EA:C055#LA:C055#
000304272 520__ $$aLymphoid neoplasms (LNs) are heterogeneous malignancies arising from lymphoid cells, displaying diverse clinical and molecular features. Although LNs are collectively frequent, individual subtypes are rare, posing challenges for genetic association studies. Indeed, genome-wide association studies (GWAS) explained only a fraction of the heritability. Shared genetic susceptibility and overlapping risk factors suggest a partially common etiology across subtypes. We employed a multi-trait GWAS strategy to improve discovery power by leveraging pleiotropy among LN subtypes. We defined LN phenoclusters based on cell of origin, somatic mutation profiles, and approved therapeutic agents. Using data from three large cohorts-the UK Biobank, Million Veteran Program, and FinnGen-we analyzed 31,937 LN cases and 1.2 million controls across 8 individual subtypes and 7 phenoclusters. We replicated the novel associations in two independent cohorts (All of Us and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) with 2892 LN cases and 165,791 controls. We identified 76 genome-wide significant loci for individual subtypes or subtype clusters, including 20 novel associations. We identified the subtypes contributing to each locus, putative candidate causal variants, and genes underlying the associations, and found enrichment of specific cell types, biological processes, and drugs associated with LN risk genes. Overall, this study identified new LN genetic risk loci and candidate genes, providing insights that may inform novel therapeutic approaches.
000304272 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000304272 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304272 650_2 $$2MeSH$$aHumans
000304272 650_2 $$2MeSH$$aGenome-Wide Association Study
000304272 650_2 $$2MeSH$$aMutation
000304272 650_2 $$2MeSH$$aFemale
000304272 650_2 $$2MeSH$$aMale
000304272 650_2 $$2MeSH$$aGenetic Predisposition to Disease
000304272 650_2 $$2MeSH$$aMiddle Aged
000304272 650_2 $$2MeSH$$aAged
000304272 7001_ $$0P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aCanzian, Federico$$b1$$eLast author$$udkfz
000304272 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/s41408-025-01351-4$$gVol. 15, no. 1, p. 147$$n1$$p147$$tBlood cancer journal$$v15$$x2044-5385$$y2025
000304272 909CO $$ooai:inrepo02.dkfz.de:304272$$pVDB
000304272 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)be2bee623c6815bb57b390a0ecb8072a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304272 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5323704270b6393dcea70186ffd86bca$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000304272 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000304272 9141_ $$y2025
000304272 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2022$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:34:04Z
000304272 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:34:04Z
000304272 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:34:04Z
000304272 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-10T15:34:04Z
000304272 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBLOOD CANCER J : 2022$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000304272 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000304272 9202_ $$0I:(DE-He78)C055-20160331$$kC055$$lGenomische Epidemiologie$$x0
000304272 9201_ $$0I:(DE-He78)C055-20160331$$kC055$$lGenomische Epidemiologie$$x0
000304272 9200_ $$0I:(DE-He78)C055-20160331$$kC055$$lGenomische Epidemiologie$$x0
000304272 980__ $$ajournal
000304272 980__ $$aVDB
000304272 980__ $$aI:(DE-He78)C055-20160331
000304272 980__ $$aUNRESTRICTED